Currax Pharmaceuticals LLC, a US-based specialty biopharmaceutical company and manufacturer of the branded oral non-GLP-1 weight loss medication brand Contrave (naltrexone HCl/bupropion HCl), announced on Tuesday the launch of its latest cost saving initiative with GoodRx, a platform for medication savings in the US.

The national access programme introduces a cash pay prescription offer for Contrave, with the intention of expanding access to affordable weight management medication for more patients, regardless of insurance.

According to the CDC, more than 40% of US adults are living with obesity, yet cost and coverage barriers often limit access to effective treatment options. Now, patients can access Contrave at a cash price of USD199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States.

Contrave is an FDA-approved, prescription-only oral medication for adults with obesity or those who are overweight with weight-related medical problems, used as an adjunct to a reduced-calorie diet and increased physical activity.